



Christopher Bowen
Managing Director and Chief Regulatory Counsel
Legal Department

November 18, 2013

VIA E-MAIL

Ms. Melissa Jurgens
Office of the Secretariat
Commodity Futures Trading Commission
Three Lafayette Centre
1155 21st Street, N.W.
Washington, D.C. 20581

**RE: Extension of the CME OTC FX Fee Waiver Program
CME Submission No. 13-455**

Dear Ms. Jurgens:

Chicago Mercantile Exchange Inc. ("CME" or the "Clearing House") hereby notifies the Commodity Futures Trading Commission ("CFTC" or "Commission") of plans to extend the existing fee waiver program supporting certain cleared-only over-the-counter ("OTC") foreign exchange ("FX") products ("Program") through June 30, 2014. The Program was set to expire on December 31, 2013 (see Submission No. 13-205). The extension will become effective on January 2, 2014. All other program terms remain unchanged.

CME reviewed the derivatives clearing organization core principles ("Core Principles") as set forth in the Commodity Exchange Act ("CEA"). During the review, CME staff concluded that the following Core Principle applies to this submission:

Financial Resources: The extension of the Program will have a non-material impact on the financial resources of the Clearing House. As such, it will not prevent the Clearing House from demonstrating that it has adequate financial, operational, and managerial resources to discharge its responsibilities as a Derivatives Clearing Organization.

Pursuant to Section 5c(c) of the CEA and CFTC Regulation 40.6(a), the Exchange hereby certifies that this Program complies with the CEA, including regulations thereunder. There were no substantive opposing views to this proposal.

CME certifies that this submission has been concurrently posted on CME's website at <http://www.cmegroup.com/market-regulation/rule-filings.html>.

If you require any additional information regarding this submission, please contact Tim Elliott at 312-466-7478 or via e-mail at tim.elliott@cmegroup.com, or contact me at 212-299-2200. Please reference our CME Submission No. 13-455 in any related correspondence.

Sincerely,

/s/ Christopher Bowen
Managing Director and Chief Regulatory Counsel